Physician profile
Michele A Spirko
NPI 1558810804
$2,201.79
in general payments reported to CMS, 2019-2025
27 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $135 · 2021: $224 · 2022: $400 · 2023: $450 · 2024: $500 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $643.53 | 2019-2024 | Spravato |
| Abbvie INC. | $195.21 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $138.42 | 2019-2025 | Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $119.46 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $113.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $98.66 | 2022-2023 | Shingrix, Bexsero |
| Astellas Pharma US INC | $93.28 | 2019-2024 | Veozah |
| Pfizer INC. | $86.52 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $83.92 | 2023-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Indivior INC. | $80.58 | 2022-2025 | Sublocade |
| Novo Nordisk INC | $56.49 | 2022-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $55.38 | 2021 | |
| Lilly USA, LLC | $53.42 | 2019-2024 | Zepbound |
| Lundbeck LLC | $47.99 | 2023-2024 | Rexulti |
| Therapeuticsmd, INC. | $42.28 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.00 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $37.92 | 2021 | |
| Corcept Therapeutics | $33.37 | 2024 | Korlym |
| Radius Health, INC. | $31.22 | 2023 | |
| Gilead Sciences, INC. | $28.96 | 2023 | |
| Impel Pharmaceuticals INC. | $21.93 | 2023 | Trudhesa |
| Amgen INC. | $19.89 | 2024 | Otezla, Repatha |
| Alkermes, INC. | $18.64 | 2021 | |
| Echosens North America, INC. | $16.84 | 2025 | Fibroscan |
| Axsome Therapeutics, INC. | $15.68 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $15.29 | 2022 | |
| Sanofi Pasteur INC. | $13.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Spirko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.